Researcher
Dirk Hendriks
- Research Expertise:Biological markers of affective disorders. Analysis of drugs and metabolites concentrations in biological matrices (serum, plasma, urine).
- Keywords:CARBOXYPEPTIDASE U, BIOLOGICAL MARKERS, DRUG DESIGN, Pharmacy and pharmacology
- Disciplines:Biochemistry and metabolism, Systems biology, Medical biochemistry and metabolism
- Research techniques:- Conceptual analysis - HPLC analysis (UV and fluorescence detection) - 3 D graphics + molecular modelling software - FPLC/BIOPILOT
- Users of research expertise:Pharmaceutical and biotech companies active in drug development
Affiliations
- Medical Biochemistry (Research group)
Member
From1 Oct 2022 → Today - Medical Biochemistry (Research group)
Member
From1 Aug 2022 → 30 Sep 2022 - Medical Biochemistry (Research group)
Member
From1 Jan 2018 → 31 Jul 2022 - Medical Biochemistry (Research group)
Responsible
From1 Oct 2003 → 31 Dec 2017
Projects
1 - 9 of 9
- Carboxypeptidase U - a new drug target for the improvement of treatment in acute ischemic stroke.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- Carboxypeptidase U - a new drug target for the improvement of treatment in acute ischemic stroke.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- The role of carboxypeptidase U in atherosclerosis and its thrombotic complications.From1 Oct 2015 → 30 Sep 2017Funding: FWO fellowships
- The role of carboxypeptidase U in atherosclerosis and its thrombotic complications.From1 Oct 2013 → 30 Sep 2015Funding: FWO fellowships
- HPLC analyses in Mood Disorder Project.From1 Dec 2011 → 31 Dec 2012Funding: Foreign foundations, funds with scientific view
- HPLC analyses in activation of the kynurenine pathway in the acute phase of stroke, and its role in depression and fatigue following stroke.From1 Dec 2011 → 31 Dec 2012Funding: Foreign foundations, funds with scientific view
- Carboxypeptidase M, substrates and ligands.From1 Oct 2010 → 31 Mar 2012Funding: FWO fellowships
- Carboxypeptidase U: a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease.From1 Oct 2009 → 31 Mar 2011Funding: FWO fellowships
- Carboxypeptidase M, substrates and ligands.From1 Oct 2008 → 30 Sep 2010Funding: FWO fellowships
Publications
1 - 10 of 36
- ProCPU is expressed by (primary) human monocytes and macrophages and expression differs between states of differentiation and activation(2023)
Authors: Karen Claesen, Joni De Loose, Pieter Van Wielendaele, Emilie De bruyn, Yani Sim, Sofie Thys, Ingrid De Meester, Dirk Hendriks
Pages: 1 - 13 - Activation of the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with SARS-CoV-2 infection could contribute to COVID-19 hypofibrinolytic state and disease severity prognosis(2022)
Authors: Karen Claesen, Yani Sim, An Bracke, Michelle De bruyn, Emilie De Hert, Gwendolyn Vliegen, An Hotterbeekx, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, et al.
Pages: 1 - 11 - The carboxypeptidase U system in atherosclerosis(2022)
Authors: Karen Claesen, Dirk Hendriks, Ingrid De Meester
Number of pages: 289 - Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients(2022)
Authors: An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, An Hotterbeekx, Isabel Brosius, et al.
Pages: 4 - 11 - Carboxypeptidase U (CPU, TAFIa, CPB2) in thromboembolic disease(2021)
Authors: Karen Claesen, Joachim Mertens, Dorien Leenaerts, Dirk Hendriks
- Effect of statin therapy on the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with hyperlipidemia(2021)
Authors: Karen Claesen, Joachim Mertens, Shahir Basir, Simon De Belder, Jeroen Maes, Johan Bosmans, Hilde Stoffelen, Ingrid De Meester, Dirk Hendriks
Pages: 908 - 916 - Carboxypeptidase U (TAFIa) is rapidly activated and deactivated following thrombolysis and thrombectomy in stroke patients(2021)
Authors: Joachim Mertens, Vanessa Blanc-Guillemaud, Karen Claesen, Pere Cardona, Dirk Hendriks, Benoit Tyl, Carlos A. Molina
- Pleiotropic effects of Atorvastatin result in a downregulation of the Carboxypeptidase U System (CPU, TAFIa, CPB2) in a mouse model of advanced atherosclerosis(2021)
Authors: Karen Claesen, Lynn Roth, Joachim Mertens, Karlijn Hermans, Yani Sim, Dirk Hendriks
- Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke(2020)
Authors: Joachim Mertens, William Boisseau, Dorien Leenaerts, Lucas Di Meglio, Stéphane Loyau, Anne-Marie Lambeir, Célina Ducroux, Martine Jandrot‐Perrus, Jean‐Baptiste Michel, Mikael Mazighi, et al.
Pages: 3325 - 3335 - The carboxypeptidase U system in acute ischemic stroke(2020)
Authors: Joachim Mertens, Dirk Hendriks, Anne-Marie Lambeir
Number of pages: 306